Bradwejn J, Koszycki D, Shriqui C
Psychopharmacology Division, St Mary's Hospital Center, Montreal, Quebec, Canada.
Arch Gen Psychiatry. 1991 Jul;48(7):603-10. doi: 10.1001/archpsyc.1991.01810310021005.
We studied the action of cholecystokinin tetrapeptide (CCK-4) in patients with panic disorder and normal controls. Subjects received, in random order, one injection of CCK-4 and one injection of placebo (saline) on two separate days in a double-blind crossover design. Two doses of CCK-4, 50 and 25 micrograms, were administered to two different samples of subjects. The panic rate with 50 micrograms of CCK-4 was 100% (12/12) for patients and 47% (7/15) for controls. The panic rate with 25 micrograms of CCK-4 was 91% (10/11) for patients and 17% (2/12) for controls. Nine percent of patients compared with 0% of controls panicked with placebo. These findings concur with previous reports of a panicogenic effect of CCK-4 and suggest that patients with panic disorder are more sensitive to the panicogenic effect of the peptide than are normal controls.
我们研究了胆囊收缩素四肽（CCK - 4）对惊恐障碍患者和正常对照者的作用。在双盲交叉设计中，受试者在两个不同的日子里随机接受一次CCK - 4注射和一次安慰剂（生理盐水）注射。将两剂CCK - 4，即50微克和25微克，分别给予两组不同的受试者样本。50微克CCK - 4注射后，患者的惊恐发生率为100%（12/12），对照者为47%（7/15）。25微克CCK - 4注射后，患者的惊恐发生率为91%（10/11），对照者为17%（2/12）。与0%的对照者相比，9%的患者在接受安慰剂注射后出现惊恐发作。这些发现与之前关于CCK - 4致惊恐作用的报道一致，并表明惊恐障碍患者比正常对照者对该肽的致惊恐作用更敏感。
